Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer
BMC Cancer Jul 12, 2019
Hirahara T, et al. - In this retrospective analysis of patients (n=175) with advanced gastric cancer treated with chemotherapy, researchers assessed the neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) and the clinical usefulness of a new blood score joining the NLR and PLR (NLR-PLR score) to see if it could predict tumor response and prognosis. Based on tumor response, patients were defined as progressive disease (PD) or non-PD. Patients with a higher NLR-PLR score demonstrated a significantly poorer prognosis vs those with a lower NLR-PLR score. NLR-PLR score was identified as an independent prognostic factor for the prediction of overall survival in multivariate analysis, as it was significantly higher in patients with PD vs those with non-PD.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries